• Explore /
  • Poster
  • / Randomized phase II study of cisplatin and etoposide versus temozolomide and capecitabine in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas (GEPNEC): A trial of the ECOG-ACRIN Cancer Research Group (EA2142).

Randomized phase II study of cisplatin and etoposide versus temozolomide and capecitabine in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine carcinomas (GEPNEC): A trial of the ECOG-ACRIN Cancer Research Group (EA2142).

Abstract Poster

Authors

null

Jennifer Rachel Eads

University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH

Jennifer Rachel Eads , Paul J. Catalano , George A. Fisher , David S. Klimstra , Zheng Zhang , Daniel Rubin , Andrei Iagaru , Terence Z. Wong , Peter J. O'Dwyer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

NCT02595424

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS4149)

DOI

10.1200/JCO.2016.34.15_suppl.TPS4149

Abstract #

TPS4149

Poster Bd #

132a

Abstract Disclosures

Similar Posters

First Author: Jennifer Rachel Eads

First Author: David E. Gerber

First Author: Primo Lara Jr.

First Author: Hidekazu Hirano